A Study of a Single Subcutaneous Dose of ALXN1210 in Healthy Adult Participants
Study Identifier:
ALXN1210-SC-101
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Other
Study Drug
- Drug: ALXN1210 SC
- Drug: ALXN1210 IV
- Drug: Placebo
Date
Aug 2016 - Jul 2017
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 25 - 55 Years
Requirements Information
Sex
Female & Male
Age
25 - 55 Years
Study Details
Medical Condition
- Other
Study Drug
- Drug: ALXN1210 SC
- Drug: ALXN1210 IV
- Drug: Placebo
Date
Aug 2016 - Jul 2017
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 25 - 55 Years years
Requirements Information
Protocol Summary
This study evaluated the safety and tolerability of a single dose of ALXN1210 subcutaneous (SC) compared to ALXN1210 intravenous (IV) in healthy participants and to determine the absolute bioavailability of ALXN1210 SC.
Trial Locations
Location
Status
Location
Clinical Trial Site
London, United Kingdom
Status
N/A